10-Q quarterly report · filed Nov 12, 2026

Kyverna Therapeutics Inc (KYTX) Q3 2026 10-Q Quarterly Report

Short answer

Kyverna Therapeutics Inc (KYTX) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$42M
−14.0% YoY · −9.5% QoQ
EPS (diluted)
−$0.67
+20.2% YoY · −6.3% QoQ

Source: XBRL data from the Kyverna Therapeutics Inc (KYTX) Q3 2026 10-Q on SEC EDGAR. USD.

Kyverna Therapeutics Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY, with no approved products or product sales
  • Net loss $41.9M vs $36.8M YoY, operating loss $42.9M vs $38.7M
  • R&D $27.0M, down 11%; G&A $15.9M, up 92%, worst cost trend
  • Cash, equivalents and marketable securities $170.6M; nine-month operating cash use $117.3M
  • SPS BLA completed in fourth quarter 2026, potential 2027 launch; funding expected for at least 12 months

Risk Factors

  • New legal risk: securities class action survived dismissal of Sections 11 and 15 claims on October 20, 2026
  • Regulatory risk: FDA CAR-T malignancy investigation could require boxed warnings, lifetime monitoring, or added post-approval obligations
  • Operational risk: miv-cel BLA submitted in fourth quarter 2026, but FDA acceptance and approval remain uncertain
  • Financial risk: $120.0 million nine-month net loss and $544.8 million accumulated deficit require substantial additional capital
  • Competitive risk: miv-cel faces approved therapies including Rituxan and Ocrevus plus emerging CAR-T and T-cell engager treatments

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.